Compare Guardant Health Inc. Common Stock (GH) vs Janus Living Inc. Class A-1 Common Stock (JAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs Janus Living Inc. Class A-1 Common Stock — how do they compare? Guardant Health Inc. Common Stock trades at $163.01 (market cap $21.74B), while Janus Living Inc. Class A-1 Common Stock trades at $29.12 (market cap $6.76B). The key difference: Guardant Health Inc. Common Stock is far larger — about 3.2× Janus Living Inc. Class A-1 Common Stock's market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.98% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 3 Days and Janus Living Inc. Class A-1 Common Stock for 0 Days on average.
| GH | JAN | |
|---|---|---|
Market Cap | $21.74B | $6.76B |
Volume | 1,297,295 | 1,332,082 |
Sector | Health | Real Estate |
52-Week High | $187.22 | $31.76 |
52-Week Low | $64.19 | $22.88 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $22.38B | $6.85B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →
